Post-trial access (PTA) to medication refers to the provision of experimental, beneficial treatments to participants after a clinical trial concludes. While not always guaranteed, it is often arranged through open-label extensions, special access schemes, or, in some cases, compassionate use programs when the drug is not yet approved.